touchIMMUNOLOGY joins Dr Sorena Kiani (Barts Health NHS Trust, London, UK) to discuss the efficacy and safety of berotralstat in the treatment of hereditary angioedema.
Questions
1. What are the unmet needs in the treatment of hereditary angioedema (HAE)? (00:17-01:53)
2. What is berotralstat and what is the rationale for its use in HAE? (01:53-03:17)
3. Could you give us a brief overview of the apeX-2 study and its findings? (03:17-06:04)
4. What did the recent data tell us about the long term efficacy and safety of berotralstat? (06:04-07:45)
5. What will be the next steps in the clinical development of berotralstat? (07:45-08:40)
Disclosures: Sorena Kiani has no financial or non-financial conflicts of interest to declare in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 2021 EAACI Annual Meeting.
